Table 2.
Least squares mean changes on efficacy measures and least squares mean endpoint improvement scores in patients treated with duloxetine or placebo
| Scale | Placebo | Duloxetine | p-value |
|---|---|---|---|
| N = 140 | N = 151 | ||
| Changes from baseline to endpoint, least squares mean (SE) | |||
| HAM-A total score | −11.7 (0.7) | −15.9 (0.6) | <0.001 |
| HAM-A Psychic Anxiety Factor score | −6.2 (0.4) | −8.6 (0.4) | <0.001 |
| HAM-A Somatic Anxiety Factor score | −5.6 (0.4) | −7.3 (0.3) | <0.001 |
| HADS Anxiety | −5.6 (0.4) | −7.8 (0.4) | <0.001 |
| HADS Depression | −1.6 (0.3) | −3.3 (0.3) | <0.001 |
| SDS Global Functional Impairment | −5.4 (0.6) | −8.6 (0.6) | <0.001 |
| Q-LES-Q-SF | 9.4 (1.5) | 15.1 (1.5) | 0.002 |
| BPI 24-h Average Pain Severity | −0.6 (0.2) | −1.1 (0.2) | 0.049 |
| BPI Pain Interference | −0.7 (0.2) | −1.2 (0.2) | 0.054 |
| Scores at endpoint, mean (SD) | |||
| CGI-I | 2.8 (1.3) | 2.3 (1.1) | <0.001 |
| PGI-I | 3.1 (1.4) | 2.5 (1.2) | <0.001 |
SE, standard error; BPI, Brief Pain Inventory; CGI-I, Clinical Global Impressions–Improvement; HADS, Hospital Anxiety and Depression Scale; HAM-A, Hamilton Anxiety Rating Scale; PGI-I, Patient Global Impression of Improvement; Q-LES-Q-SF, Quality of Life Enjoyment and Satisfaction Questionnaire–Short Form; SDS, Sheehan Disability Scale.